KAILERA THERAPEUTICS INC (KLRA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$16.23+3.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · KLRA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
KLRA — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition. On August 12, 2026, Kailera Therapeutics, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended June 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securi…
Why it matters: Starting this trial would show progress in making a new obesity treatment. Good results could grow Kailera's product line.
Supportive ifAnnouncement of KAI-4729 Phase 1 trial initiation by the end of 2026.
Worry ifNo announcement of trial initiation by the end of 2026.
Why it matters: A drop in sector revenue growth could signal broader challenges for Kailera. It may affect its performance.
Worry ifSector revenue growth has been below its average for two quarters in a row.
Less concerning ifSector revenue growth has stayed above its average for two quarters in a row.
Why it matters: The earnings report will show if the company can recover from the recent miss. Investors will look for signs of improvement.
Watch forEarnings per share (EPS) exceeds the consensus estimate by more than 10%.
Also watch forEPS falls short of the consensus estimate by more than 10%.
Why it matters: Updates on Hengrui's trials may show how well ribupatide works. Good results could boost Kailera's trust.
Watch forHengrui shares good topline data from ribupatide trials. They show significant weight loss.
Also watch forHengrui shares disappointing data from ribupatide trials. They show only a little weight loss.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$279 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $693 loss on $10,000 · 6.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,077 loss on $10,000 · 40.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Good data would show ribupatide could be a top treatment for obesity.
Supportive ifThe global Phase 3 KaiNETIC program for ribupatide shows it helps people lose weight.
Worry ifData from the Phase 3 trials fails to show meaningful weight loss compared to placebo.
Why it matters: If the company misses earnings again, it may worry investors. This could raise concerns about its financial health.
Worry ifAnother earnings report shows a loss greater than the previous quarter's miss.
Less concerning ifNext earnings report shows a profit or smaller loss than the previous quarter.
Why it matters: Starting these trials in early 2027 could show strong progress for Kailera's oral obesity treatment. This would support their oral formulation plan.
Supportive ifThey will announce the start of global Phase 3 trials for ribupatide oral in early 2027.
Worry ifNo announcement of trial initiation by mid-2027.
Why it matters: This data will show how well the high-dose ribupatide injection works for obesity. Good results could increase trust in Kailera's products.
Supportive ifData from the Phase 2b trial shows significant weight loss, exceeding 10% from baseline.
Worry ifData shows no significant weight loss, below 5% from baseline.
Why it matters: Good data could improve Kailera's place in the obesity treatment market. It will show how well this oral GLP-1 receptor agonist works.
Supportive ifData from the Phase 2 trial shows significant weight loss, exceeding 10% from baseline.
Worry ifData shows no significant weight loss, below 5% from baseline.